Familial homozygous hypercholesterolaemia

The PBS subsidises evolocumab for patients with familial homozygous hypercholesterolaemia.

Treatment with evolocumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with familial homozygous hypercholesterolaemia.  

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing evolocumab.


Patients must be treated by or in consultation with a consultant physician. The date of the consultation must be no more than 6 months before the application for a PBS authority.

Initial treatment

Make all initial applications for authority approval to prescribe evolocumab for the treatment of familial homozygous hypercholesterolaemia in writing and:

All initial applications must include a completed:

A qualifying low density lipoprotein (LDL) cholesterol level must be provided at the time of application and be no more than 2 months old.

Continuing treatment

To make an application for continuing treatment, call the PBS Complex Drugs Programs enquiry line.

Further information

For more information call the PBS Complex Drugs Programs enquiry line.

We’re testing a new website design. Try it out and tell us what you think. Read more about changes to this site.

Page last updated: 5 December 2016

This information was printed Thursday 17 August 2017 from humanservices.gov.au/health-professionals/enablers/familial-homozygous-hypercholesterolaemia It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.